These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16635181)

  • 1. Successful recombinant erythropoietin therapy for a developing anemic newborn with hereditary spherocytosis.
    Hosono S; Hosono A; Mugishima H; Nakano Y; Minato M; Okada T; Takahashi S; Harada K
    Pediatr Int; 2006 Apr; 48(2):178-80. PubMed ID: 16635181
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recombinant Human Erythropoietin (r-HuEPO) therapy in a newborn with hereditary spherocytosis].
    Schiff M; Haÿs S; Sann L; Putet G
    Arch Pediatr; 2003 Apr; 10(4):333-6. PubMed ID: 12818755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis.
    Tchernia G; Delhommeau F; Perrotta S; Cynober T; Bader-Meunier B; Nobili B; Rohrlich P; Salomon JL; Sagot-Bevenot S; del Giudice EM; Delaunay J; DeMattia D; Schischmanoff PO; Mohandas N; Iolascon A;
    Hematol J; 2000; 1(3):146-52. PubMed ID: 11920183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant erythropoietin vs. blood transfusion care in infants with hereditary spherocytosis: a retrospective cohort study of A.I.E.O.P. patients (Associazione Italiana Emato-Oncologia Pediatrica).
    Farruggia P; Puccio G; Ramenghi U; Colombatti R; Corti P; Trizzino A; Barone A; Boscarol G; Ferraro F; Grotto P; Lo Valvo L; Luti L; Matarese SMR; Mosa C; Putti MC; Rubert L; Ruffo GB; Sainati L; Tartaglione I; Russo G; Perrotta S
    Am J Hematol; 2017 Jun; 92(6):E103-E105. PubMed ID: 28263406
    [No Abstract]   [Full Text] [Related]  

  • 5. [Recombinant erythropoietins--an alternative therapy to red cell blood transfusions in infants with hereditary spherocytosis].
    Neuman-Łaniec M; Wierzba J; Irga N; Wasilewska E; Balcerska A
    Przegl Lek; 2002; 59(10):871-2. PubMed ID: 12632932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting anemia with erythropoietin during critical illness.
    Cook D; Crowther M
    N Engl J Med; 2007 Sep; 357(10):1037-9. PubMed ID: 17804850
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients.
    Levine AM; Salvato P; Leitz GJ;
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):131-9. PubMed ID: 18284320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients.
    Saag MS; Bowers P; Leitz GJ; Levine AM;
    AIDS Res Hum Retroviruses; 2004 Oct; 20(10):1037-45. PubMed ID: 15587490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoetin alfa: to give or not to give.
    Dang C; Hudis C; Norton L
    J Natl Cancer Inst; 2013 Jul; 105(14):1001-3. PubMed ID: 23860203
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral ascorbic acid as adjuvant to epoetin alfa in hemodialysis patients with hyperferritinemia.
    Nguyen TV
    Am J Health Syst Pharm; 2004 Oct; 61(19):2007-8. PubMed ID: 15509119
    [No Abstract]   [Full Text] [Related]  

  • 11. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
    Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
    Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
    Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?
    Macdougall IC; Roche A; Rossert J; Casadevall N; Francois P; Kemeny DM
    Nephrol Dial Transplant; 2004 Nov; 19(11):2901-5. PubMed ID: 15496566
    [No Abstract]   [Full Text] [Related]  

  • 14. Erythropoiesis stimulating agents: a personal journey.
    Leyland-Jones B
    J Natl Cancer Inst; 2013 Jul; 105(14):999-1001. PubMed ID: 23860202
    [No Abstract]   [Full Text] [Related]  

  • 15. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of erythropoietin-stimulating agents versus supportive care in newborns with hereditary spherocytosis: a single centre's experience.
    Morrison JF; Neufeld EJ; Grace RF
    Eur J Haematol; 2014 Aug; 93(2):161-4. PubMed ID: 24660843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
    Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
    Longfield V; Gebhart B; Hayward L
    J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoietin in patients with ST-segment elevation myocardial infarction.
    Chen Y
    JAMA; 2011 Aug; 306(7):705-6; author reply 706. PubMed ID: 21846847
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluating the effectiveness of epoetin alfa in community oncology practices.
    Harris Spiridonidis C; Brinkmannb K; Fridman M; Gupta S; Tannous RE
    Hematology; 2003 Aug; 8(4):243-8. PubMed ID: 12911942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.